In 2027, Medicare will pay about 21% less for a wound treatment in clinics, but about 15% more at hospitals.
Sanuwave Health (SNWV) announced that Medicare will pay 21% less for its Ultramist therapy in clinics but 15% more in hospitals starting in 2027. The company disputes the clinic payment reduction, citing incomplete data, and plans to engage with CMS. Sanuwave focuses on wound care and regenerative medicine technologies.
How this was made
The 30-second read
Why it matters
The office-setting payment reduction could compress SNWV's margins, while the hospital outpatient increase may partially offset the impact.
Market read
Regulatory change directly affects SNWV's reimbursement rates, creating short-term downside risk.
What to watch
Potential for future CMS adjustments or successful lobbying could reverse the cut.
Background
CMS released its 2027 Physician Fee Schedule and Hospital Outpatient Prospective Payment System rules, adjusting payment rates for CPT code 97610.
Ticker impact
CMS 2027 rule reduces Medicare payment for SNWV's Ultramist therapy in office settings, potentially lowering revenue.
likely downward pressure as market prices in the reimbursement cut.
The payment reduction directly affects SNWV's core product pricing, which may hurt earnings outlook.
Market effects
May signal tighter Medicare reimbursement for advanced wound care devices, affecting peers.
U.S. healthcare reimbursement environment.
Limited to U.S. Medicare policy impact.
Counterpoint
If SNWV can secure alternative payer contracts, the impact may be muted.
Key entities
- CompanySanuwave Health, Inc.
Provider of FDA-cleared directed energy systems for wound care.
- RegulatorCenters for Medicare & Medicaid Services (CMS)
U.S. agency issuing the reimbursement rule.
